Tharimmune Acquires Global License and Partners With Intract Pharma to Develop Oral Infliximab

Tharimmune, Inc., a biotechnology company, has announced a definitive agreement with Intract Pharma. The partnership includes an exclusive license for INT-023/TH023, an oral anti-TNF-α infliximab. This agreement aims to expand Tharimmune's therapeutic pipeline for autoimmune diseases.

Tharimmune gains global development and commercialization rights to Intract's Soteria® and Phloral® delivery platforms, alongside an infliximab supply agreement. Intract Pharma receives an upfront payment, with potential future equity financing and milestone payments, as well as royalties. Tharimmune retains a right of first refusal post-Phase 2 clinical trial and options for four additional targets.

Infliximab, traditionally administered intravenously, faces challenges in oral delivery due to gastrointestinal complexities. Leveraging Intract's platform, this partnership aims to develop an oral pill form, potentially improving patient compliance and reducing healthcare burdens.

Randy Milby, CEO of Tharimmune, emphasized the potential of integrating Intract's technology and high-quality infliximab, citing this collaboration as a strategic move to compete in a multibillion-dollar market. Vipul Yadav, CEO of Intract, highlighted the partnership's significance in addressing long-term medical needs in chronic inflammation and immune-mediated diseases.